Lynk Pharmaceuticals and Simcere announced Strategic Commercialization Partnership

18 March 2022 | Friday | News


On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. (Lynk Pharmaceuticals) and Simcere (2096.HK) announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.
Image Source : Public Domain

Image Source : Public Domain

Under the terms of the agreement, Lynk Pharmaceuticals is responsible for the development of the product. Simcere will obtain the exclusive rights to market LNK01001 for the indications of rheumatoid arthritis and ankylosing spondylitis in China, after completing the payment of all commercialization rights and interests.

JAK1 belongs to an important subgroup of the cytosolic tyrosine kinase Janus kinase (JAKs) family that is closely related to the pathogenesis of various autoimmune diseases. 6 head-to-head clinical studies have demonstrated the huge clinical potential of selective JAK1 inhibitor as an emerging new treatment of rheumatoid arthritis, with significant advantages over methotrexate and several biological agents. Published data of JAK1 inhibitor as treatment of ankylosing spondylitis have shown sufficient superiority of JAK1 inhibitor in a head-to-head study over Humira, the TNFα targeting blockbuster. Selective JAK1 inhibitors are thus considered to be the next superstar of therapies.

LNK01001 is a highly selective JAK1 inhibitor with therapeutic potential for various autoimmune diseases. Clinical trials in Chinese and western patient groups are being carried out, including phase II studies in China in three indications of rheumatoid arthritis, ankylosing spondylitis, and atopic dermatitis. Previously, LNK01001 has completed Phase I clinical studies in healthy subjects in China and Australia. The results of preclinical data show that LNK01001 has higher selectivity and potentially better safety than other marketed JAK inhibitors. It is expected to provide patients with newer, safer and more effective treatment options.

"We are very pleased to have reached the commercialization cooperation  of LNK01001 with Simcere in China. It marks a big step forward towards commercialization for Lynk through Simcere's marketing strength." Said Dr. Zhao-Kui (ZK) Wan, founder & CEO of Lynk Pharmaceuticals, "Simcere is an innovation and R&D-driven company that ranks among top Chinese pharmaceutical enterprises. Its proven commercialization excellence, combining with our R & D capability, will likely to create more benefit for the patients sooner."

Mr. Jinsheng Ren, Chairman and CEO of Simcere said: "Autoimmune disease therapeutic are one of Simcere's three strategic focuses. We are very pleased to have reached this cooperation with Lynk Pharmaceuticals. We will work closely with our partner with all efforts, and accelerate the development and commercialization process of LNK01001, to bring safer and more effective treatments to patients."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close